




**CORRECTION**      **OPEN**

# Correction To: Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass loss

Chen Kan , Jiazhao Yang, Haitao Fan, Yuanjuan Dai, Xingxing Wang, Rui Chen, Jia Liu, Xiangyue Meng, Wei Wang, Guiling Li, Jiao Zhou, Ya Zhang, Wanbo Zhu, Shiyuan Fang, Haiming Wei, Hong Zheng , Siying Wang and Fang Ni 

*Bone Research* (2022)10:64

; <https://doi.org/10.1038/s41413-022-00238-5>

Correction to: *Bone Research* <https://doi.org/10.1038/s41413-022-00232-x>, published online 27 October 2022

Following publication of this article<sup>1</sup>, it is noticed that a sentence “FetA was characterized as a decoy receptor of transforming growth factor beta (TGF- $\beta$ )/BMP, suggesting that FetA could be useful to inhibit and/or prevent TGF- $\beta$ /BMP-induced diseases, including heterotopic ossification<sup>61,62,63,64</sup>.” needs to be inserted in the section DISCUSSION. References 61–64 are also added.

In addition, the reference number “2019YFA0801801” should be changed to “2019YFA0801800” in the section ACKNOWLEDGEMENTS.

The original article<sup>1</sup> was updated.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

**REFERENCE**

1. Kan, C. et al. Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass loss. *Bone Res.* **10**, 62 (2022).